Hercules Pharmaceuticals is a pioneering brand that specializes in the development of innovative oral drug therapies for the treatment of cancer and viral infections. One of their main focuses is blocking the Aryl Hydrocarbon Receptor (AhR), which has shown promising results in enhancing the immune system's response to cancer and reducing tumor growth in multiple solid tumor models. Additionally, Hercules' AhR inhibitors have proven effective in blocking viral replication in models of viral infection, including ZIKA and Dengue viruses.

Notably, AhR is highly expressed in patients with Covid-19 infection, suggesting that Hercules' AhR inhibitors may also be able to block replication of the coronavirus. With ongoing research and financial support, Hercules aims to develop oral treatments for patients with early symptoms of Covid-19 and other viral infections. Join the fight against cancer and viral diseases with Hercules Pharmaceuticals